Michael Zile to Dose-Response Relationship, Drug
This is a "connection" page, showing publications Michael Zile has written about Dose-Response Relationship, Drug.
Connection Strength
0.471
-
Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure. J Am Coll Cardiol. 2016 Dec 06; 68(22):2425-2436.
Score: 0.102
-
A phase II, double-blind, randomized, placebo-controlled, dose comparative study of the efficacy, tolerability, and safety of MCC-135 in subjects with chronic heart failure, NYHA class II/III (MCC-135-GO1 study): rationale and design. J Card Fail. 2004 Jun; 10(3):193-9.
Score: 0.043
-
Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. J Am Heart Assoc. 2021 02 16; 10(4):e019238.
Score: 0.034
-
Rationale and design for a multicenter, randomized, double-blind, placebo-controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF). Am Heart J. 2020 04; 222:183-190.
Score: 0.032
-
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trial. Eur J Heart Fail. 2019 03; 21(3):337-341.
Score: 0.030
-
Role of High-Dose Beta-Blockers in Patients with Heart Failure with Preserved Ejection Fraction and Elevated Heart Rate. Am J Med. 2018 12; 131(12):1473-1481.
Score: 0.029
-
Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2018 04; 20(4):760-768.
Score: 0.028
-
Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF. Eur Heart J. 2017 04 14; 38(15):1132-1143.
Score: 0.026
-
The effects of sacubitril/valsartan on coronary outcomes in PARADIGM-HF. Am Heart J. 2017 Jun; 188:35-41.
Score: 0.026
-
Influence of Sacubitril/Valsartan (LCZ696)?on?30-Day Readmission After Heart Failure Hospitalization. J Am Coll Cardiol. 2016 07 19; 68(3):241-248.
Score: 0.025
-
Relevance of Changes in Serum Creatinine During a Heart Failure Trial of Decongestive Strategies: Insights From the DOSE Trial. J Card Fail. 2016 Oct; 22(10):753-60.
Score: 0.025
-
Efficacy of sacubitril/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2016 Oct; 18(10):1228-1234.
Score: 0.025
-
Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response. Eur J Heart Fail. 2015 Sep; 17(9):925-35.
Score: 0.023
-
A randomized, double-blind, placebo-controlled study of the safety and efficacy of intravenous MCC-135 as an adjunct to primary percutaneous coronary intervention in patients with acute myocardial infarction: Evaluation of MCC-135 for left ventricular salvage in acute myocardial infarction (EVOLVE). Am Heart J. 2008 Jan; 155(1):113.e1-8.
Score: 0.014
-
Direct effects of acute administration of 3, 5, 3' triiodo-L-thyronine on myocyte function. Ann Thorac Surg. 1994 Sep; 58(3):851-6.
Score: 0.005
-
Effects of protamine on myocyte contractile function and beta-adrenergic responsiveness. Ann Thorac Surg. 1994 May; 57(5):1066-74; discussion 1074-5.
Score: 0.005